AMELIA GLEBER: Open Payments
NPI 1427548593 · SPRINGDALE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 18 payments from 11 companies in 2025. Trend: 2023 $643 · 2024 $438 · 2025 $574
Food & beverage: $496Education: $78
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 2 | $139 |
| PharmaEssentia USA Corporation | 2 | $135 |
| Gilead Sciences, Inc. | 1 | $78 |
| Janssen Biotech, Inc. | 4 | $73 |
| ABBVIE INC. | 2 | $41 |
| Celgene Corporation | 2 | $31 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Aveo Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Novartis Pharmaceuticals Corporation | 1 | $14 |
Products named: Jakafi, BESREMI, Trodelvy, TECVAYLI, VENCLEXTA, CARVYKTI, XPOVIO, FOTIVDA.
Industry payments across AR — which companies pay providers there.
